

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3107236

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
STEPHANE BANCEL	10/07/2014
TIRTHA CHAKRABORTY	10/07/2014
ANTONIN DE FOUGEROLLES	10/09/2014
SAYDA M. ELBASHIR PHD	10/07/2014
MATTHIAS JOHN	10/07/2014
ATANU ROY	10/20/2014
SUSAN WHORISKEY	10/13/2014
KRISTY M. WOOD	10/24/2014
PAUL HATALA	10/29/2014
KENECHI EJEBE	10/20/2014
JEFF LYNN ELLSWORTH	10/16/2014
JUSTIN GUILD	10/07/2014

**RECEIVING PARTY DATA**

<b>Name:</b>	MODERNA THERAPEUTICS, INC.
<b>Street Address:</b>	200 TECHNOLOGY SQUARE
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02139

**PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14390097

**CORRESPONDENCE DATA**

Fax Number: (978)448-8721

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 9784488720

Email: docketing@dtwardlaw.com

Correspondent Name: DT WARD, PC

Address Line 1: 142A MAIN STREET

Address Line 4: GROTON, MASSACHUSETTS 01450

**PATENT**

<b>ATTORNEY DOCKET NUMBER:</b>	2030.1301US371
<b>NAME OF SUBMITTER:</b>	ANITA M. COSTA
<b>SIGNATURE:</b>	/Anita M. Costa/
<b>DATE SIGNED:</b>	11/13/2014

**Total Attachments: 27**

source=Assignment#page1.tif  
source=Assignment#page2.tif  
source=Assignment#page3.tif  
source=Assignment#page4.tif  
source=Assignment#page5.tif  
source=Assignment#page6.tif  
source=Assignment#page7.tif  
source=Assignment#page8.tif  
source=Assignment#page9.tif  
source=Assignment#page10.tif  
source=Assignment#page11.tif  
source=Assignment#page12.tif  
source=Assignment#page13.tif  
source=Assignment#page14.tif  
source=Assignment#page15.tif  
source=Assignment#page16.tif  
source=Assignment#page17.tif  
source=Assignment#page18.tif  
source=Assignment#page19.tif  
source=Assignment#page20.tif  
source=Assignment#page21.tif  
source=Assignment#page22.tif  
source=Assignment#page23.tif  
source=Assignment#page24.tif  
source=Assignment#page25.tif  
source=Assignment#page26.tif  
source=Assignment#page27.tif

### ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date 10/7/14 Signature   
Name Stephane Bancel

Date 10/07/2014 Signature   
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougères

Date 10/07/2014 Signature   
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date 10/07/14 Signature *Justin Guild*  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date October 9, 2014 Signature   
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES

Filed: October 2, 2014

Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild



## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougères

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date 10/20/2014 Signature   
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date 10/07/2014 Signature   
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date 10/07/2014 Signature   
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougères

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.


Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy



Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date 10/13/14 Signature   
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougères

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES

Filed: October 2, 2014

Application No.: 14/390,097

---

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Susan Whoriskey

Date 10/24/14

Signature 

Name Kristy M. Wood

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Paul Hatala

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Jason P. Schrum

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Kenechi Ejebe

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Jeff Lynn Ellsworth

Date \_\_\_\_\_

Signature \_\_\_\_\_

Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date 29 Oct 2014 Signature   
Name Paul Hafala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not



hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---


Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kenechi Ejebe

Date 10-16-14  
~~10-15-16~~ Signature   
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/390,097, entitled "MODIFIED POLYNUCLEOTIDES", filed October 2, 2014.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Sayda M. Elbashir, Ph.D.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Matthias John

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Atanu Roy

Title: MODIFIED POLYNUCLEOTIDES  
Filed: October 2, 2014  
Application No.: 14/390,097

---

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Kristy M. Wood

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Paul Hatala

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jason P. Schrum

Date 10/20/14 Signature   
Name Kenechi Ejebe

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Jeff Lynn Ellsworth

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Justin Guild